^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) + Fyarro (nanoparticle albumin-bound rapamycin) (mTORC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5484 / 2 - Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts
Published date:
03/15/2023
Excerpt:
This study investigated the antitumor activity of nab-s in combination with KRASis in KRAS G12C NSCLC and bladder xenograft models….nab-S in combination with either sot or ada showed synergistic antitumor activity compared to the SA.
